Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TYMS | P04818 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29793269 | 1.00 | MAOB (0.47) | MAOBMAOAPARP1ALDH1A1HPGD | |
| SCHEMBL14750041 | 0.78 | PSMB5 (0.45) | MAOBMAOAALDH1A1HPGDHSD17B10 | |
| SCHEMBL29955280 | 0.76 | KCNJ1 (0.49) | MAOBMAOAPARP1ALDH1A1HPGD | |
| SCHEMBL30991499 | 0.75 | MAOB (0.47) | MAOBMAOAPARP1ALDH1A1HPGD | |
| SCHEMBL87504 | 0.75 | MAOB (0.47) | MAOBMAOAALDH1A1HPGDHSD17B10 | |
| SCHEMBL856025 | 0.75 | MAOB (0.47) | MAOBMAOAALDH1A1HPGDHSD17B10 | |
| SCHEMBL2045834 | 0.75 | MAOB (0.47) | MAOBMAOAPARP1ALDH1A1HPGD | |
| SCHEMBL698199 | 0.75 | PIM1 (0.48) | MAOBMAOAALDH1A1HPGDHSD17B10 | |
| SCHEMBL7639394 | 0.75 | KCNJ1 (0.51) | MAOBMAOAPARP1ALDH1A1HPGD | |
| SCHEMBL32672785 | 0.75 | MAOB (0.47) | MAOBMAOAALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234957-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2022-12-29 | — | — | US | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| WO-2021262591-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| CN-107853517-B | Traditional Chinese medicine beverage capable of refreshing and resisting fatigue and preparation method thereof | 辽宁中医药大学 | 2021-04-27 | — | — | CN | disclosed |
| WO-2020162471-A1 | PYRIDONE DERIVATIVE | マルホ株式会社 | 2020-08-13 | — | — | WO | disclosed |
| US-20190309289-A1 | PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING | ENEVOLV, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10370654-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2019-08-06 | — | — | US | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093032-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-07-30 | — | — | WO | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | MAOB 43/4885MAOA 85/4885PARP1 3253/4885 |
| US-20220411372-A1 | SMALL-MOLECULE INHIBITORS FOR THE B-CATENIN/B-CELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION | BCL9, BCL9L, BCL6 | MAOB 3297/4885MAOA 4527/4885PARP1 2812/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | MAOB 43/4885MAOA 85/4885PARP1 3253/4885 |
| US-20090192156-A1 | PHTHALAZINONE DERIVATIVES | CBR1, CBR3, SDHA | MAOB 458/4885MAOA 915/4885PARP1 1973/4885 |
| US-10370366-B2 | Pyridazinone compounds and methods for the treatment of cystic fibrosis | CFTR, SLC26A4, PNPO | MAOB 545/4885MAOA 1428/4885PARP1 3414/4885 |
| US-20230234957-A1 | PROTEIN TAG TO INDUCE LIGAND DEPENDENT DEGRADATION OF PROTEIN/PROTEIN-FUSIONS | BET1, STUB1, MDM2 | MAOB 4189/4885MAOA 3775/4885PARP1 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.